tbuckley/cabot-search huggingface dataset:
Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses
Authors: Carlo Finelli, Sarah Parisi, Matilde Y Follo, Cristina Clissa, Miriam Fogli, Sara Mongiorgi, Costanza Bosi, Isabella Capodanno, Barbara Castagnari, Anna Candoni, Monica Crugnola, Maria Benedetta Giannini, Giovanna Leonardi, Maurizio Miglino, Gian Matteo Rigolin, Domenico Russo, Patrizia Tosi, Andrea Pellagatti, Jacqueline Boultwood, Lucio Cocco, Michele Cavo
Journal: Blood (2020)
Minimal Residual Disease Assessment and Allogeneic Transplantation As Consolidation Therapy in Acute Lymphoblastic Leukemia
Authors: Jf Combariza, Leonardo Bautista Toloza, M Arango, L Diaz, Claudia Agudelo Lopez, Vladimir Avila, Sonia Milena Hernandez, Guillermo León-Basantes, Ana Maria Madera Rojas, Jaime valdés-Cespedes, Fabián Mejia, Liliana Moreno, Rocio Orduz R, Jl Tovar-Bobadilla, Carlos Alberto Ramirez
Journal: Blood (2020)
The Novel Dihydroorotate Dehydrogenase (DHODH) Inhibitor PTC299 Inhibit De Novo Pyrimidine Synthesis with Broad Anti-Leukemic Activity Against Acute Myeloid Leukemia
Authors: Sujan Piya, Marla Weetall, Josephine Sheedy, Balmiki Ray, Huaxian Ma, Kensuke Kojima, Vivian Ruvolo, Mahesh Basyal, Marina Konopleva, Michael Andreeff, Gautam Borthakur
Journal: Blood (2020)
Assisted dying: Campaigners leave Dignity in Dying over law change policy only for people with less than six months to live
Authors: Jacqui Wise
Journal: BMJ (2020)

Several Welsh campaigners for assisted dying have left the organisation Dignity in Dying because they disagree with its policy of restricting a change in the law to people with no more than six months to live.

Miriam Day, orthopaedic surgeon and specialist in musculoskeletal trauma at Cwm Taf Morgannwg University Health Board, was until recently the key campaigner in Cardiff’s Dignity in Dying group. She and nine others, of 12 active members, decided to leave Dignity in Dying after learning that its policy would not help people such as Paul Lamb, a man paralysed from the neck down. They have now joined the group My Death, My Decision (MDMD), which is calling for a broader change to the law to include terminally ill people and those with incurable suffering.

Day told The BMJ , “Dignity in Dying never made their policy transparent to me—you had to really search in the small print to find that they are only campaigning …
Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia
Authors: Johannes Bloehdorn, Andrejs Braun, Billy Michael Chelliah Jebaraj, Amaro Taylor-Weiner, Sandra Robrecht, Julia Krzykalla, Karlheinz Holzmann, Harvey Johnston, Tetyana Klymenko, Barbara Eichhorst, Ru-Fang Yeh, Martin Weisser, Jennifer Edelmann, Kirsten Fischer, John G. Gribben, Dan A. Landau, Donna S. Neuberg, Mark S Cragg, Axel Benner, Michael Hallek, Catherine J. Wu, Hartmut Döhner, Stephan Stilgenbauer, Daniel Mertens
Journal: Blood (2020)
CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions
Authors: Victor M. Orellana-Noia, Daniel R Reed, Jeremy M Sen, Christian Barlow, Mary-Kate Malecek, Brad S. Kahl, Michael A Spinner, Ranjana Advani, Timothy J Voorhees, Anson Snow, Natalie S Grover, Amy Ayers, Jason T. Romancik, Yuxin Liu, Scott F. Huntington, Julio C. Chavez, Hayder Saeed, Aleksandr Lazaryan, Vikram Raghunathan, Stephen E. Spurgeon, Thomas A Ollila, Christopher Del Prete, Adam J Olszewski, Emily C. Ayers, Daniel J. Landsburg, Benjamin Echalier, Jun Lee, Manali Kamdar, Paolo F Caimi, Timothy Fu, Jieqi Liu, Kevin A. David, Hanan Alharthy, Jennie Y. Law, Reem Karmali, Harsh Shah, Deborah M. Stephens, Ajay Major, Alexandra E Rojek, Sonali M. Smith, Amulya Yellala, Avyakta Kallam, Shazia Nakhoda, Nadia Khan, Jonathon B. Cohen, Craig A. Portell
Journal: Blood (2020)
Characteristics of and Risk Factors for Monoclonal Gammopathy of Undetermined Significance (MGUS) in the Multiethnic Cohort Study
Authors: Maryam Salehi, Daniel O. Stram, Jose A Aparicio, Liliana Aguinada, Victoria K. Cortessis, Maximo J. Marin, Loic Le Marchand, Christopher Haiman, Lynne Wilkens, Jane Emerson, Wendy Cozen
Journal: Blood (2020)
Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)
Authors: Michael U. Callaghan, Claude Négrier, Ido Paz-Priel, Tiffany Chang, Sammy Chebon, Michaela Lehle, Johnny Mahlangu, Guy Young, Rebecca Kruse-Jarres, Maria Elisa Mancuso, Markus Niggli, Peter Kuebler, Nives Selak Bienz, Midori Shima, Victor Jimenez-Yuste, Christophe Schmitt, Elina Asikanius, Gallia Levy, Steven W. Pipe, Johannes Oldenburg
Journal: Blood (2020)
Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn’s Disease: A Meta-Analysis of Population-Based Cohorts
Authors: Lester Tsai, Christopher Ma, Parambir S. Dulai, Larry J. Prokop, Samuel Eisenstein, Sonia L. Ramamoorthy, Brian G. Feagan, Vipul Jairath, William J. Sandborn, Siddharth Singh
Journal: Clinical Gastroenterology and Hepatology (2020)
Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231
Authors: David T. Teachey, Meenakshi Devidas, Brent L Wood, Zhiguo Chen, Robert James Hayashi, Robert D Annett, Barbara L Asselin, Keith J August, Steve Y Cho, Kimberly P. Dunsmore, Brian T. Fisher, Jason L. Freedman, Paul J. Galardy, Paul Harker-Murray, Michelle L. Hermiston, Terzah M Horton, Alok I Jaju, Allison Lam, Yoav H. Messinger, Rodney R. Miles, Maki Okada, Samir I Patel, Eric S. Schafer, Tal Schechter-Finkelstein, Kristin A. Shimano, Neelam Singh, Amii C. Steele, Maria L. Sulis, Sarah L Vargas, Stuart S. Winter, Charlotte Wood, Patrick Zweider McKay, Catherine M. Bollard, Mignon L. Loh, Stephen P. Hunger, Elizabeth A. Raetz
Journal: Blood (2020)
Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor–modulating agent
Authors: Robert Bissonnette, Linda Stein Gold, David S. Rubenstein, Anna M. Tallman, April Armstrong
Journal: Journal of the American Academy of Dermatology (2020)

Tapinarof, a novel, first-in-class, small-molecule topical therapeutic aryl hydrocarbon receptor (AhR)-modulating agent, is in clinical development for the treatment of psoriasis and atopic dermatitis. The efficacy of tapinarof in psoriasis is attributed to its specific binding and activation of AhR, a ligand-dependent transcription factor, leading to the downregulation of proinflammatory cytokines, including interleukin 17, and regulation of skin barrier protein expression to promote skin barrier normalization. AhR signaling regulates gene expression in immune cells and skin cells and has critical roles in the regulation of skin homeostasis. Tapinarof-mediated AhR signaling underlies the mechanistic basis for the significant efficacy and acceptable tolerability observed in early-phase clinical trials of tapinarof cream in the treatment of psoriasis.
Parsing multiomics landscape of activated synovial fibroblasts highlights drug targets linked to genetic risk of rheumatoid arthritis
Authors: Haruka Tsuchiya, Mineto Ota, Shuji Sumitomo, Kazuyoshi Ishigaki, Akari Suzuki, Toyonori Sakata, Yumi Tsuchida, Hiroshi Inui, Jun Hirose, Yuta Kochi, Yuho Kadono, Katsuhiko Shirahige, Sakae Tanaka, Kazuhiko Yamamoto, Keishi Fujio
Journal: Annals of the Rheumatic Diseases (2020)

Objectives Synovial fibroblasts (SFs) are one of the major components of the inflamed synovium in rheumatoid arthritis (RA). We aimed to gain insight into the pathogenic mechanisms of SFs through elucidating the genetic contribution to molecular regulatory networks under inflammatory condition. Methods SFs from RA and osteoarthritis (OA) patients (n=30 each) were stimulated with eight different cytokines (interferon (IFN)-α, IFN-γ, tumour necrosis factor-α, interleukin (IL)-1β, IL-6/sIL-6R, IL-17, transforming growth factor-β1, IL-18) or a combination of all 8 (8-mix). Peripheral blood mononuclear cells were fractioned into five immune cell subsets (CD4 + T cells, CD8 + T cells, B cells, natural killer (NK) cells, monocytes). Integrative analyses including mRNA expression, histone modifications (H3K27ac, H3K4me1, H3K4me3), three-dimensional (3D) genome architecture and genetic variations of single nucleotide polymorphisms (SNPs) were performed. Results Unstimulated RASFs differed markedly from OASFs in the transcriptome and epigenome. Meanwhile, most of the responses to stimulations were shared between the diseases. Activated SFs expressed pathogenic genes, including CD40 whose induction by IFN-γ was significantly affected by an RA risk SNP (rs6074022). On chromatin remodelling in activated SFs, RA risk loci were enriched in clusters of enhancers (super-enhancers; SEs) induced by synergistic proinflammatory cytokines. An RA risk SNP (rs28411362), located in an SE under synergistically acting cytokines, formed 3D contact with the promoter of metal-regulatory transcription factor-1 (MTF1) gene, whose binding motif showed significant enrichment in stimulation specific-SEs. Consistently, inhibition of MTF1 suppressed cytokine and chemokine production from SFs and ameliorated mice model of arthritis. Conclusions Our findings established the dynamic landscape of activated SFs and yielded potential therapeutic targets associated with genetic risk of RA.
A Phase II Study of Bisantrene in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Authors: Jonathan Canaani, Ivetta Danilesko, Noga Shem-Tov, Maya Zlotnick, Kira Lozinsky, Ohad Benjamini, Ronit Yerushalmi, Meital Nagar, Chen Dor, Avichai Shimoni, Abraham Avigdor, Arnon Nagler
Journal: Blood (2020)
Genetic Background of Chronic Active Epstein-Barr Virus Disease
Authors: Yusuke Okuno, Takayuki Murata, Yoshitaka Sato, Hideki Muramatsu, Norihiro Murakami, Tatsuya Okuno, Kenichi Yoshida, Yoshinori Ito, Akihisa Sawada, Koichi Ohshima, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Satoru Miyano, Yoshiyuki Takahashi, Seiji Kojima, Seishi Ogawa, Hiroshi Kimura
Journal: Blood (2017)
Autologous Stem Cell Transplantation (ASCT) for T-Cell Non Hodgkin Lymphoma (T-NHL) Patients Who Achieve Complete Remission with First-Line Treatment: A Systematic Review and Meta-Analysis
Authors: Yin Jie Koh, Louis-Pierre Girard, Hian Li Esther Hian Li Chan, Joanne Shu Xian Lee, Yen-Lin Chee, Anand Jeyasekharan, Sanjay de Mel, Cinnie Yentia Soekojo, Xin Liu, Liang Piu Koh, Michelle Poon, Miny Samuel
Journal: Blood (2020)
Myelodysplastic Syndromes (MDS) &amp; COVID-19: Clinical Experience from the US Epicenter of the Pandemic
Authors: Jonathan Feld, Erin P. Demakos, Rosalie Odchimar-Reissig, Douglas Tremblay, Saudia Alli, Darshanie Sewah, Shyamala C. Navada, Lewis R. Silverman
Journal: Blood (2020)
Abstract GMM-054: AN INVESTIGATION OF THE EFFECTS OF THE ATYPICAL PKC-ζ INHIBITOR ζ-STAT ON CLEAR CELL CARCINOMA OVARIAN CANCER PROLIFERATION AND INVASION
Authors: Tracess Smalley, Rekha Patel, Mildred Acevedo-Duncan
Journal: Clinical Cancer Research (2019)

Abstract Ovarian cancer is the most lethal gynecological cancer diagnosis. There is no efficient screening process for ovarian cancers and the average stage of diagnosis is stage III. The most common ovarian cancer diagnosis is epithelial ovarian carcinomas, which constitute for 85-90% of prognosis; of this percent, clear cell ovarian carcinoma (CCOC) represents 5% of incidence. CCOC presents unique pathological features and has a high reoccurrence rate after treatment. An overexpression of atypical PKCs (PKC-ζ and PKC-ι/λ) has been observed in various malignant cells lines and are linked to pathways for cellular proliferation and invasion. In this investigation, ovarian cell lines (TOV21G and ES-2) were treated with the atypical PKC-ζ inhibitor ζ-Stat and assayed to determine the effects on proliferation and cellular invasion. These assays included protein quantification, cell proliferation, and wound healing. Mouse xenograph experiments were also performed to determine the effects of ζ-Stat on TOV21G tumor growth in vivo. Our data shows that ζ-Stat decreases the proliferation of clear cell carcinoma ovarian cancer cells and decreases wound healing. Our results also show that tumor growth in athymic female mice is decreased when treated with ζ-Stat and that mouse body weight is maintained. This suggests that PKC-ζ is a novel target in carcinogenesis and inhibition of this protein decreases the rate of proliferation. Citation Format: Tracess Smalley, Rekha Patel, Mildred Acevedo-Duncan. AN INVESTIGATION OF THE EFFECTS OF THE ATYPICAL PKC-ζ INHIBITOR ζ-STAT ON CLEAR CELL CARCINOMA OVARIAN CANCER PROLIFERATION AND INVASION [abstract]. In: Proceedings of the 12th Biennial Ovarian Cancer Research Symposium; Sep 13-15, 2018; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2019;25(22 Suppl):Abstract nr GMM-054.
Thromboembolism in Patients with Advanced Renal Cell Carcinoma Treated with Immunotherapy
Authors: Iris Yeong- Fung Sheng, Shilpa Gupta, Chandana A Reddy, Dana E Angelini, Pauline Funchain, Joanna Roopkumar, Tamara A. Sussman, Joseph Sleiman, Timothy D Gilligan, Moshe C Ornstein, Alok A Khorana
Journal: Blood (2020)
Abstract 220: Emerging Roles of Altered NAD Metabolism in Diabetic Cardiomyopathy
Authors: Chi Fung Lee
Journal: Circulation Research (2020)

Diabetes is linked to altered NAD metabolism whose causal roles in cardiac dysfunction are poorly understood. Synthesis, consumption and redox balance of NAD dictate NAD metabolism and its homeostasis, and we here explored their roles in diabetic cardiomyopathy. 16 week of Type 1 diabetes (T1D) to C57BL6N mice was associated with lowered cardiac NAD/NADH, mild systolic and more severe diastolic dysfunction. We next used mouse models with altered NAD metabolism to determine how NAD redox balance impacts diabetic cardiomyopathy. Using cardiac-specific Ndufs4-KO mice (cKO) as a model of latent decrease in cardiac NAD/NADH, we observed accelerated systolic and diastolic dysfunction (lowered fractional shortening, E’/A’ ratio, and increased e/E’ ratio) in male cKO mice stressed with chronic T1D. Cardiac hypertrophy (heart weight/tibia length), insulin depletion and hyperglycemia levels were similar in these mice. Serum metabolomic analyses (~240 metabolites) also showed unchanged aqueous and lipid metabolite levels, suggesting that the diabetic stresses on these hearts were similar. The accelerated dysfunction of T1D cKO hearts was also observed in another female cohort. Importantly, elevation of cardiac NAD levels to attenuate NAD redox imbalance mitigated the accelerated dysfunction of T1D cKO hearts. In another cohort, control and cKO mice were stressed by 16-week high fat diet feeding. Accelerated systolic and diastolic dysfunction, and increased hypertrophy were observed in T2D cKO mice with similar glycemic levels to control mice. The data suggested that NAD redox imbalance is a positive regulator of cardiac dysfunction induced by T1D or T2D. However, NAD-dependent pathogenic mechanism induced by T1D or T2D (e.g. hypertrophy) can be different, and is under further investigation. Tissue fibrosis and mRNA levels of pro-fibrotic genes, including Adamts proteinases, integrins, laminins, matrix metalloproteinases and collagens were unchanged in T1D cKO hearts. Therefore, the accelerated dysfunction of T1D cKO hearts is due to cardiomyocyte dysfunction. We examined how NAD metabolism, other than the redox balance, may alter cardiomyocyte function. Levels of metabolite and mRNA regulating NAD synthesis and consumption pathways were measured. Of 32 transcripts assayed, Nmrk2 levels were uniquely up-regulated in T1D cKO hearts, and lowered by elevation of cardiac NAD levels. NMRK product levels were concomitantly decreased in T1D cKO hearts. NAD-dependent global acetylation and inhibitory superoxide dismutase 2 acetylation were increased in T1D cKO hearts. Protein oxidation levels were concomitantly raised. Hyperacetylation in proteins like CaM kinase was associated with increased phosphorylation in troponin I, not in MyBPC or PLN in T1D cKO hearts. These data support the emerging, multifaceted roles of altered NAD metabolism in the progression of diabetic cardiomyopathy.
A CHIP in the Armor of Cell-Free DNA–Based Predictive Biomarkers for Prostate Cancer
Authors: Zachery R. Reichert, Morgan A. Jones, Joshi J. Alumkal
Journal: JAMA Oncology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
The Utility of Granulocyte Colony Stimulating Factor in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy with Axicabtagene Ciloleucel
Authors: Jason N Barreto, Corina J Doleski, Justin R Hayne, Matthew A Hathcock, Tuan A Truong, Stephen M. Ansell, Nabila Bennani, Jonas Paludo, Jose C Villasboas, Yi Lin, Patrick B. Johnston
Journal: Blood (2020)
Modulation of the Tumor Suppressor Protein PP2A Using a Small Molecule Agonist Overcomes Multi-Drug Resistance through Mitochondrial Permeability Transition Pore (MPTP) Dependent Induction of Apoptosis in Chronic Lymphocytic Leukemia
Authors: Kallesh D. Jayappa, Caroline Farrington, Vicki L. Gordon, Shekhar Saha, Christopher Morris, Krista M. Isaac, Timothy P. Bender, Michael E. Williams, Craig A. Portell, Goutham Narla, Michael J. Weber
Journal: Blood (2020)
Discrimination of Breast Cancer from Healthy Breast Tissue Using a Three-component Diffusion-weighted MRI Model
Authors: Maren M. Sjaastad Andreassen, Ana E. Rodríguez-Soto, Christopher C. Conlin, Igor Vidić, Tyler M. Seibert, Anne M. Wallace, Somaye Zare, Joshua Kuperman, Boya Abudu, Grace S. Ahn, Michael Hahn, Neil P. Jerome, Agnes Østlie, Tone F. Bathen, Haydee Ojeda-Fournier, Pål Erik Goa, Rebecca Rakow-Penner, Anders M. Dale
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Diffusion-weighted MRI (DW-MRI) is a contrast-free modality that has demonstrated ability to discriminate between predefined benign and malignant breast lesions. However, how well DW-MRI discriminates cancer from all other breast tissue voxels in a clinical setting is unknown. Here we explore the voxelwise ability to distinguish cancer from healthy breast tissue using signal contributions from the newly developed three-component multi-b-value DW-MRI model. Experimental Design: Patients with pathology-proven breast cancer from two datasets (n = 81 and n = 25) underwent multi-b-value DW-MRI. The three-component signal contributions C1 and C2 and their product, C1C2, and signal fractions F1, F2, and F1F2 were compared with the image defined on maximum b-value (DWImax), conventional apparent diffusion coefficient (ADC), and apparent diffusion kurtosis (Kapp). The ability to discriminate between cancer and healthy breast tissue was assessed by the false-positive rate given a sensitivity of 80% (FPR80) and ROC AUC. Results: Mean FPR80 for both datasets was 0.016 [95% confidence interval (CI), 0.008–0.024] for C1C2, 0.136 (95% CI, 0.092–0.180) for C1, 0.068 (95% CI, 0.049–0.087) for C2, 0.462 (95% CI, 0.425–0.499) for F1F2, 0.832 (95% CI, 0.797–0.868) for F1, 0.176 (95% CI, 0.150–0.203) for F2, 0.159 (95% CI, 0.114–0.204) for DWImax, 0.731 (95% CI, 0.692–0.770) for ADC, and 0.684 (95% CI, 0.660–0.709) for Kapp. Mean ROC AUC for C1C2 was 0.984 (95% CI, 0.977–0.991). Conclusions: The C1C2 parameter of the three-component model yields a clinically useful discrimination between cancer and healthy breast tissue, superior to other DW-MRI methods and obliviating predefining lesions. This novel DW-MRI method may serve as noncontrast alternative to standard-of-care dynamic contrast-enhanced MRI.
Abstract 358: Hypoxia and Hyperglycemia Induces M <sup>6</sup> A Mrna Methylation in Major Heart Cells
Authors: Rajesh Kumari, Prabhat Ranjan, Zainab Suleiman, Jing Li, Suresh K Verma
Journal: Circulation Research (2020)

Background: According to American heart association, over 70 % diabetic patients die from heart and stroke related diseases. The term “diabetic heart diseases” includes coronary heart disease, heart failure and diabetic cardiomyopathy in diabetic patients. Epigenetic and epitranscriptomic modifications play critical roles in progress of diabetic heart disease. Recent evidences indicated that m 6 A methylation involved in ischemic cardiomyopathy. But, the role of m 6 A mRNA methylation in cardiovascular diseases along with diabetic co-morbidity factors has not been studied in details. Thus, here we hypothesize that alterations in m 6 A mRNA methylation under hypoxic and hyperglycemic conditions contributes to severity of ischemic heart disease. Method and Results: To address our hypothesis, we have determined the levels of m 6 A mRNA methylation in NRVM, NRVF and HUVEC, HMVE and mouse primary endothelial cells under hypoxic and hyperglycemic conditions. We also examined the m 6 A levels in mice hearts post 5 days of MI. m 6 A mRNA methylation was significantly upregulated both in human and mouse ischemic hearts. Furthermore, hypoxia and hyperglycemia significantly induced m 6 A methylation in neonatal rat cardiomyocytes, fibroblasts, and mouse primary endothelial cells (isolated from WT and db/db mice). Next, we measured the methylation machinery both at RNA and protein levels. Interestingly, in corroboration with our methylation data, the expression of both m 6 A writers (Mettl3 and WTAP) and Readers (YTHDF2) was significantly increased. To determine the target transcripts which were highly methylated post-ischemia, we performed deep sequencing of methylated RNA after their immunoprecipitation using MeRIP-sequencing protocol. Our MeRIP-seq data has suggested a differentially m 6 A methylated targets both in-vitro and in-vivo ischemic sample. Conclusion: Over all, for the first time our data showed that hypoxia and hyperglycemia alters m 6 A mRNA methylation which may contribute to enhance the severity of cardiovascular diseases under hyperglycemic conditions. Further understanding of the mechanisms, may present a novel approach to potentially regulate m 6 A methylation, which may help in preventing/reducing heart failure in diabetic patients.
Survival in Patients Who Underwent HLA-Haploidentical Stem Cell Transplantation in Two Centers in Colombia
Authors: Lisbeth Ramirez, Juan Manuel Herrera, Angela María Peña, Maria Luna-Gonzalez, Claudia Marcela Chalela, Luis Antonio Salazar, Sara Ines Jimenez, Manuel Rosales, Alvaro Guerrero, Margarita Velasco, Robinson Pacheco, Jose Sandoval-Sus, Claudia Lucia Sossa
Journal: Blood (2020)